CureVac N.V. (ETR:5CV)
Germany
· Delayed Price · Currency is EUR 2.718
-0.068 (-2.44%)
Mar 31, 2025, 2:35 PM CET
CureVac Revenue
CureVac had revenue of 14.44M EUR in the quarter ending June 30, 2024, with 90.47% growth. This brings the company's revenue in the last twelve months to 65.86M, up 75.12% year-over-year. In the year 2023, CureVac had annual revenue of 53.76M, down -20.26%.
Revenue (ttm)
65.86M
Revenue Growth
+75.12%
P/S Ratio
n/a
Revenue / Employee
60.64K
Employees
1,172
Market Cap
617.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.16B |
| Siemens Healthineers AG | 22.67B |
| Fresenius SE & Co. KGaA | 21.83B |
| Bayer Aktiengesellschaft | 46.61B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.34B |
| Carl Zeiss Meditec AG | 2.08B |
| Fielmann Group AG | 2.16B |
CureVac News
- 2 days ago - CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions - Seeking Alpha
- 2 days ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 3 days ago - European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
- 3 days ago - European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
- 3 days ago - European Patent Office declares CureVac mRNA patent valid - Reuters
- 3 days ago - CureVac up 13% as court upholds validity of patent in BioNTech spat - Seeking Alpha
- 3 days ago - CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Wallstreet:Online
- 3 days ago - CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Accesswire